Jinxin Fertility Group Limited (JXR) announced that it is assessing the launch of an asset-backed securities programme (ABS Programme) to be listed on the Shanghai Stock Exchange. The initiative would see a single class of asset-backed securities issued against real-estate assets held by the Group’s subsidiary, Shenzhen Hengyu Lianxiang Investment Development Co., Ltd., whose building in Shenzhen’s Futian District currently serves Shenzhen Zhongshan Hospital.

Management expects the proposed transaction to significantly lower the Group’s leverage ratio and enhance capital structure and asset quality. If executed, the deal could be classified as a deemed disposal of Hengyu under Rule 14.29 of the Hong Kong Listing Rules.

Implementation remains contingent on market conditions and approvals from the China Securities Regulatory Commission, the Shanghai Stock Exchange and the Hong Kong Stock Exchange. Detailed terms, including issuance size and timetable, have not yet been finalised. JXR has committed to publishing further updates in accordance with listing requirements.

Shareholders and potential investors are advised that the transaction may or may not proceed, and to exercise caution when dealing in the Company’s securities.